Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK's Lost Quarter: $3 Billion DoJ Settlement Far Outstrips Net Profit

This article was originally published in The Pink Sheet Daily

Executive Summary

If approved, the settlement would set a new record for the pharmaceutical industry in its dealings with the federal government, but would be covered by the firm's existing reserves.

You may also be interested in...



EU Pharma Ups Share Buybacks In 2012

Share buybacks are controversial in the biopharma industry, but European pharma companies, facing tough operating environments and pressures on near-term financials, are planning to invest in them in 2012 more than in recent years.

GSK’s Deal With DoJ Is Fourth In Eight Years; Exec Liability Uncertain

GlaxoSmithKline PLC’s toughest negotiations this year have been with the federal government.

No End In Sight: Pharma Companies Continue To Face Government Probes

Related Content

Topics

UsernamePublicRestriction

Register

PS073006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel